Cartesian Therapeutics In... (RNAC)
18.44
0.42 (2.33%)
At close: Jan 15, 2025, 11:18 AM
undefined% (undefined)
| Bid | 18.4 |
| Market Cap | 474.37M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -55.43 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 18.59 |
| Volume | 28,685 |
| Avg. Volume (20D) | 122,262 |
| Open | 18.58 |
| Previous Close | 18.02 |
| Day's Range | 18.12 - 18.65 |
| 52-Week Range | 11.66 - 41.87 |
| Beta | undefined |
About RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2016
Employees 37
Stock Exchange NASDAQ
Ticker Symbol RNAC
Website https://selectabio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for RNAC stock is "Buy." The 12-month stock price forecast is $41.5, which is an increase of 125.05% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
Next Earnings Release
Cartesian Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025,
before market opens.
Analysts project revenue of $100.00K, reflecting a -98.79% YoY shrinking and earnings per share of -0.83, making a -98.01% decrease YoY.
Analysts project revenue of $100.00K, reflecting a -98.79% YoY shrinking and earnings per share of -0.83, making a -98.01% decrease YoY.
6 months ago ·
Source
-35.02%
Cartesian Therapeutics shares are trading lower. T...
Unlock content with
Pro Subscription
8 months ago ·
Source
+12.76%
Cartesian Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.
